AVDL Avadel Pharmaceuticals ADS

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:

  • Wells Fargo Healthcare Conference: Fireside chat on Thursday, September 7 at 4:30 p.m. ET.
  • H.C. Wainwright 25th Annual Global Investment Conference: Fireside chat on Monday, September 11 at 10:00 a.m. ET.
  • Cantor Global Healthcare Conference: Company presentation on Thursday, September 28 at 1:15 p.m. ET.

A live webcast of these events, as well as an archived recordings, will be available on Avadel’s Investor Relations website, , for 90 days following each conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. For more information, please visit .

Investor Contact:

Courtney Turiano

Stern Investor Relations, Inc.



(212) 698-8687

Media Contact:

Lesley Stanley

Real Chemistry



(609) 273-3162



EN
31/08/2023

Underlying

AVDLAvadel Pharmaceuticals ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Avadel Pharmaceuticals ADS

 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlemen...

Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlement DUBLIN, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the global settlement of all litigation with Jazz Pharmaceuticals Inc. (“Jazz”). Under the primary terms of the settlement agreement, Avadel and Jazz will dismiss their respective lawsuits with prejudice. Furthermore, Jazz agrees to grant Avadel the following: A perpetual, worldwide license to any past, present, or future patents that c...

October 22, 2025 1 EN
 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule ...

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to seven (7) new employees to purchase 161,600 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rul...

October 13, 2025 1 EN
 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Slee...

Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding DUBLIN, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The American Academy of Sleep Medicine Foundation (AASM Foundation) and Avadel Pharmaceuticals are celebrating five years of collaboration and dedicated support for early-career sleep researchers and future sleep physicians. In 2021, Avadel became the Young Investigator Research Forum’s (YIRF) inaugural corporate sponsor. Thanks to support from Avadel and other companies, YIRF has empowered dozens of trainees and junior faculty in sleep and circadi...

September 16, 2025 1 EN
 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule ...

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to five (5) new employees to purchase 165,520 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rul...

September 10, 2025 1 EN
 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate)...

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025 – 17 abstracts accepted, including one oral presentation – – Data from the REFRESH real-world study highlight efficacy of once-nightly sodium oxybate when switching from twice-nightly oxybates – – REFRESH study also highlights efficacy in those who were new to oxybate or returning to oxybate after discontinuing twice-nightly oxybate – DUBLIN, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company f...

September 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch